Innodata Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. Innodata provides AI data preparation and deployment services and operates its Digital Data Solutions (DDS), Synodex and Agility segments. Amounts below are in U.S. dollars; financial figures are in millions unless stated otherwise.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 or prior date |
|---|---|---|
| Revenue | $18.839 | $21.192; down 11% |
| Gross profit / gross margin | $5.965 / 32% | $7.778 / 37% |
| Selling and administrative expenses | $7.797 | $10.190; down 24% |
| Net loss attributable to Innodata | $(2.116); $(0.08) per share | $(2.815); $(0.10) per share |
| Adjusted EBITDA (non-GAAP) | $0.801 | $(1.002) |
| Operating cash flow | $1.784 | $(1.496) |
| Capital expenditures | $1.702 | $1.939 |
| Cash and cash equivalents | $10.330 | $9.792 at Dec. 31, 2022 |
| Short-term investments | $0.512 | $0.507 at Dec. 31, 2022 |
| Working capital | $2.323 | $2.869 at Dec. 31, 2022 |
Operating cash flow less capital expenditures was approximately $0.082 million. Cash flow benefited from lower receivables and increases in accrued salaries and taxes. The company reported total assets of $49.135 million and stockholders’ equity of $18.418 million at quarter-end.
At March 31, long-term obligations totaled $7.409 million, including $6.239 million in accrued pension liability and $1.170 million for software licenses; $1.121 million was current. Operating lease liabilities totaled $4.559 million. These are distinct from the revolving credit facility entered into after quarter-end.
Changes versus the prior-year quarter
- DDS revenue fell 20% to $12.746 million, primarily on lower volume from one customer; DDS gross margin declined to 33% from 41%.
- Synodex revenue increased 12% to $1.865 million. The segment moved from a gross loss to $0.203 million gross profit and was approximately breakeven on net income.
- Agility revenue increased 17% to $4.228 million, mainly on higher subscriptions and newswire volumes. Its net loss narrowed to $1.503 million from $2.879 million.
- Lower selling and administrative expenses and cost optimization helped narrow the consolidated GAAP net loss. However, reported gross margin declined to 32% from 37%, reflecting lower DDS revenue and weaker DDS margins.
Adjusted gross profit was $7.420 million and adjusted gross margin 39%, compared with $8.669 million and 41% a year earlier. These are non-GAAP measures; adjustments include depreciation and amortization, stock-based compensation and non-recurring severance. Adjusted EBITDA also includes such adjustments and should not be read as GAAP profit or cash flow.
Outlook, commentary and risks
- Management said existing cash and internally generated funds were expected to meet financial needs for at least 12 months from the filing date. It anticipated approximately $6.5 million in capital expenditures over the next 12 months, including software development and technology infrastructure.
- On April 4, 2023, the company entered into a secured revolving facility with a stated maximum of $10 million, subject to a borrowing base. The calculated borrowing base at entry was approximately $3.3 million. Borrowings bear interest at daily simple SOFR plus 2.25%; a fixed-charge coverage ratio of at least 1.10 to 1.00 is required by December 31, 2023. The facility is secured and carries operating and financial covenants.
- Management cited project-based DDS work, customer project reductions or cancellations, customer concentration, competition, technology and cybersecurity risks, foreign exchange and wage-cost exposure, and uncertainty in converting pipeline opportunities into work. Two DDS customers each represented approximately 11% of Q1 revenue.
- Tax and legal contingencies include a disputed Indian service-tax matter relating to approximately $57 million of subsidiary revenue from 2012–2016, potentially subject to tax of 12.36%–15% plus interest and penalties if the tax authority prevails; no liability was recorded. The company also disclosed a Philippine former-employee judgment with a potential payment of approximately $5.9 million plus accrued interest, subject to ongoing U.S. court proceedings. Management said adverse outcomes in these matters could materially affect results. Other adverse legal outcomes of approximately $450,000 beyond recorded amounts were described as reasonably possible.
- Q1 included $0.580 million of non-recurring severance in the company’s Adjusted EBITDA reconciliation, associated with a headcount reduction and cost-structure realignment. The filing reports effective disclosure controls as of March 31, 2023.
The filing provides no specific full-year revenue or earnings guidance. Management’s liquidity and capital-spending expectations are not guarantees of future results.
Important facts for investors to verify
- Whether DDS revenue and margins stabilize, particularly given customer concentration and project-based work.
- Whether cost reductions translate into sustained GAAP profitability, rather than relying on non-GAAP adjustments.
- Actual revolver availability under the borrowing-base formula, borrowing costs, and the company’s ability to meet the December 2023 covenant.
- Cash generation relative to planned capital spending and working-capital needs.
- Developments in the Indian tax dispute and Philippine litigation, including any change to recorded liabilities or potential exposure.